Quantitative analysis for ALX Oncology Holdings Inc. (ALXO) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Hold (50.0) (grade C). Gem alpha score: 52.0. 32 signals analyzed (26 differentiated alt-data).
ALXO stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $1.67 | $1.57 | $1.58 |
| 2026-05-11 | $2.13 | $2.01 | $2.08 |
| 2026-05-21 | $2.02 | $1.97 | $1.99 |
| 2026-06-03 | $1.80 | $1.67 | $1.67 |
| 2026-06-15 | $1.61 | $1.56 | $1.58 |
| 2026-06-26 | $2.13 | $1.77 | $2.04 |
| 2026-07-09 | $2.41 | $2.05 | $2.06 |
| 2026-07-21 | $2.09 | $1.91 | $2.05 |
| 2026-07-31 | $2.00 | $1.85 | $1.94 |
| 2026-08-12 | $2.02 | $1.90 | $2.01 |
| 2026-08-24 | $2.03 | $1.95 | $1.99 |
| 2026-09-03 | $2.09 | $2.00 | $2.03 |
How ALX Oncology Holdings Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| OWLT | Owlet, Inc. | $108M | — |
| VOR | Vor Biopharma Inc. | $107M | — |
| NAKA | Nakamoto Inc. | $110M | — |
| GNLX | Genelux Corporation | $110M | — |
View all Health Care stocks by valuation and signals →
ALX Oncology Holdings Inc. (ALXO) scores Hold (50.0), and the composite conceals a 63-point disagreement between its dimensions. It is strongest on competitive moat at 93 and earnings quality at 82, and weakest on technicals at 30. A stock can carry competitive moat that high while technicals sits at 30; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 93 |
| earnings quality | 82 |
| valuation | 72 |
| AI Alpha (gem) | 68 |
| ML forecast | 48 |
| analyst consensus | 45 |
| technicals | 30 |
StoQuant analyzes 32 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on ALX Oncology Holdings Inc. (ALXO): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ALXO"><img src="https://stoquant.com/badge/ALXO.svg" alt="ALX Oncology Holdings Inc. (ALXO) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.